Healthcare work can involve sustained pressure, exposure to suffering and difficult decisions made with inadequate resources. Depression and occupational burnout may develop together, but they are different clinical concerns. Small randomised trials suggest that psilocybin-supported treatment can reduce depressive symptoms in selected healthcare workers. A specific, lasting benefit for burnout has not yet been established.
The strongest findings concern short-term improvement in depression among clinicians affected by frontline work during the COVID-19 pandemic. Burnout outcomes are less convincing. Treatment for an individual’s distress also needs to sit alongside measures addressing the working conditions that contribute to it.
On this page
- Burnout and depression require separate assessment
- What the first controlled trial found
- Adding group treatment to mindfulness training
- Which outcomes would demonstrate recovery?
- Why workplace conditions remain part of treatment
- Selection, safety and follow-up
- Confidentiality and freedom to decline
- Care that can proceed now
Burnout and depression require separate assessment
The World Health Organization classifies burnout as an “occupational phenomenon”. Its definition concerns chronic workplace stress associated with exhaustion, increased distance or cynicism towards work, and reduced professional effectiveness. It is not classified as a medical condition in ICD-11, and its occupational definition should not be extended to every form of distress.1
Depression, by contrast, warrants a clinical assessment of mood, loss of interest, associated symptoms, duration and impairment. A clinician who describes being burnt out may also have major depression, an anxiety disorder, PTSD or another condition requiring treatment. Occupational language should neither obscure a treatable disorder nor turn every understandable response to difficult work into a psychiatric diagnosis.
Assessment should consider sleep, substance use, physical health, suicidal thinking and previous episodes of activation as well as current symptoms. The person’s professional knowledge does not remove the need for independent care. Familiarity with diagnostic language can coexist with difficulty recognising deterioration in oneself or seeking help.
What the first controlled trial found
A 2024 randomised trial enrolled 30 physicians, advanced practice practitioners and nurses with moderate-to-severe depressive symptoms after frontline pandemic work. Participants had no reported pre-pandemic mental-health diagnosis. Fifteen received psilocybin and 15 received niacin, with preparation and integration support in both groups. At day 28, the mean improvement on the Montgomery–Åsberg Depression Rating Scale was 12 points greater in the psilocybin group; the 95% confidence interval was approximately 6.3–17.7 points.2
Burnout scores also improved numerically more with psilocybin, but the between-group finding was not statistically significant. That distinction matters: the primary depression result cannot be used as proof that the intervention treats occupational burnout. The trial was small, and a comparison with niacin does not eliminate the possibility that participants recognised their allocation from the marked subjective effects.2
Adding group treatment to mindfulness training
A second randomised study, published in 2025, enrolled 25 physicians and nurses with pandemic-related depression and burnout symptoms. Both groups received an eight-week mindfulness-based stress reduction programme. One group additionally received psilocybin-assisted group psychotherapy. At two weeks after the intervention, the combined treatment produced an approximately 4.6-point greater improvement in self-reported depression on the QIDS-SR-16 scale, with a 95% confidence interval of 1.51–7.70 points.3
The between-group advantage waned by six-month follow-up. Burnout, demoralisation and connectedness findings favoured the combined intervention initially, but did not remain statistically significant after correction for multiple comparisons. Twelve study-related adverse events of mild-to-moderate severity were recorded, with no serious adverse events reported.3
This study tested a treatment package rather than the isolated effect of psilocybin. The combined arm received substantially more intervention, and participants knew which programme they were receiving. Additional therapist contact, group support and expectation could contribute to the difference. A larger study with closer matching of psychological care is needed to clarify how much benefit the drug itself adds.3
Which outcomes would demonstrate recovery?
| Outcome | Clinical significance | Current limitation |
|---|---|---|
| Depression | Reduced low mood, loss of interest and related symptoms. | Encouraging short-term findings in small, selected clinical samples. |
| Burnout | Less occupational exhaustion and disengagement, with restored effectiveness. | A reliable treatment-specific benefit has not been demonstrated. |
| Daily functioning | Better sleep, relationships, concentration and participation in life. | Symptom scores alone do not establish functional recovery. |
| Sustainable work | A return to, or continuation of, work under manageable conditions. | The trials do not establish durable changes in staffing, workload or organisational culture. |
A reduction in depression is valuable even when occupational problems persist. Equally, improvement on a rating scale should not be equated with readiness to resume an unchanged workload. Recovery may involve altered duties, protected time away from work or a reconsideration of professional commitments. Those decisions need their own assessment and should remain separate from enthusiasm about a treatment experience.
Why workplace conditions remain part of treatment
WHO guidance recommends organisational action to address psychosocial risks at work, alongside support for individuals. Relevant measures include identifying and modifying harmful working conditions, responding to violence or harassment, involving workers in decisions and enabling reasonable adjustments. Psychological treatment can help a person respond to distress; it cannot by itself provide adequate staffing or remove an unsafe system.4
The same distinction applies to moral distress: an individual may feel troubled by care they were unable to provide or decisions constrained by resources. Treatment should permit discussion of those circumstances without assuming the problem is simply inadequate personal resilience. This is a clinical and ethical implication of the occupational context, rather than an outcome established by the psilocybin trials.
A service evaluating a new treatment should therefore ask two questions: whether the person benefits, and whether avoidable contributors to their distress are being addressed. An intervention may fail to produce sustained recovery if the person returns to the same unresolved pressures. That possibility should be investigated rather than attributed automatically to insufficient motivation or integration.
Selection, safety and follow-up
The trial populations were narrower than the healthcare workforce as a whole. Both studies focused on pandemic-related difficulties, and the mindfulness trial involved a small, relatively homogeneous group. These findings cannot automatically be applied to clinicians with longstanding recurrent illness, active substance dependence, acute suicidality or substantially different psychiatric histories.3
Screening and follow-up need to address both psychological and physical suitability. A clinician’s ability to describe a protocol accurately does not establish personal suitability for it. Assessment should include current medication, cardiovascular concerns, previous mania or psychosis, and the availability of support after treatment. These requirements are discussed further in the collection’s article on psychedelic therapy safety.
Follow-up needs to capture deterioration, persistent distress and nonresponse as well as improvement. The absence of a serious event in a small trial provides limited reassurance about uncommon harms. A favourable session should not close clinical review when sleep, judgement, anxiety or functioning later worsen.
Confidentiality and freedom to decline
Healthcare workers may have particular concerns about disclosure, employment and professional standing. A treatment service should explain what is recorded, who can access it and how clinical information is separated from workplace decisions. The mindfulness trial restricted public release of individual-level data partly because of the sensitivity of information from a small professional population.3
Group treatment adds another consideration. Participants need clear expectations about confidentiality and must be free to limit personal disclosure. A colleague’s positive experience should not create pressure to participate, and refusal of an experimental intervention should not be interpreted as a lack of commitment to recovery or patient care.
These are standards for the design of a responsible service, not claims that every existing programme meets them. Consent should also explain the possibility that additional support will be needed after the formal intervention ends.
Care that can proceed now
Depression treatment should be selected collaboratively according to severity, previous response, clinical needs and preferences. Established options include psychological treatment and medication where appropriate, with monitoring of benefit, adverse effects and suicidal thinking. Uncertainty about psilocybin should not delay assessment or access to established care.5
Occupational support and return-to-work planning belong alongside clinical treatment. WHO guidance addresses reasonable adjustments and coordinated support for participation in work; recovery should not be reduced to an individual’s ability to endure the previous workload.6
Further trials need longer follow-up, more representative participants and outcomes that distinguish depression from burnout and sustained occupational functioning. Current evidence supports further investigation of psilocybin for depression in selected healthcare workers. It does not justify presenting a psychedelic intervention as an established solution to the conditions producing burnout.
References
- World Health Organization. Burn-out an occupational phenomenon: International Classification of Diseases. 28 May 2019; accessed 11 October 2026.
- Back AL, Freeman-Young TK, Morgan L, et al. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2024;7:e2449026. doi:10.1001/jamanetworkopen.2024.49026.
- Lewis BR, Hendrick J, Byrne K, et al. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLoS Med. 2025;22:e1004519. doi:10.1371/journal.pmed.1004519.
- World Health Organization. Mental health at work. Fact sheet; accessed 11 October 2026.
- National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). Recommendations; accessed 11 October 2026.
- World Health Organization. WHO guidelines on mental health at work. 2022. ISBN 9789240053052; accessed 11 October 2026.